Art. -Nr.: HY-116439

Diisononyl phthalate

Name: Diisononyl phthalate
Brand: MedChemExpress
SKU: HY-116439
Price: 25.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: DINP)

Kundenbewertung

Based on 1 Customer Validation

Diisononyl phthalate (DINP) is an orally active polyvinyl chloride plasticizer and indirect food additive. Diisononyl phthalate activates the ACE/AT1R axis and inhibits the production of NO. Diisononyl phthalate reduces the expression of eNOS. Diisononyl phthalate induces increased blood pressure in mice. Diisononyl phthalate induces monocytic leukemia in rats. Diisononyl phthalate can be used in hypertension-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98.0%
CAS. Nr.: 28553-12-0
Formel: C₂₆H₄₂O₄
Molecular Weight:418.61

Speicherung:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Diisononyl phthalate Chemical Structure

CAS. Nr.: 28553-12-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

AT1 Receptor

eNOS

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen :

In Vitro

Diisononyl phthalate shows no genotoxic activity in bacterial and mammalian cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Exposure to diisononyl phthalate alone (0.15-15 mg/kg/day; intragastric administration; daily; 42 days) induces dose-dependent elevation of blood pressure, increased heart rate (at 15 mg/kg/day), and cardiovascular/renal tissue damage in C57/BL6 mice, accompanied by upregulated expression of ACE and AT1R in the aorta, downregulated expression of eNOS in the aorta, and reduced serum NO production^[1].
Exposure to diisononyl phthalate (0.15-15 mg/kg/day; oral gavage; daily; 42 days; with simultaneous daily subcutaneous administration of 1 mg/kg/day dexamethasone for 42 days) dose-dependently exacerbates dexamethasone-induced hypertension, cardiovascular/renal tissue damage, and dysregulation of the ACE/AT1R and eNOS/NO pathways in C57/BL6 mice, and this effect is reversible by treatment with an ACE inhibitor^[1].
Dietary intake of diisononyl phthalate (DINP) at doses of 0.03-0.6 wt% daily for 2 years induces a dose-dependent increase in liver, kidney and spleen weights in Fischer 344 rats. Male rats in the high-dose group show a slight decrease in body weight, and rats in the middle- and high-dose groups exhibit a statistically significant increase in the incidence of monocytic leukemia over the 2-year experimental period^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57/BL6 (male, 5-6 weeks old, ~20 g, specific pathogen free)^[1]
Dosage:

0.15 mg/kg/day; 1.5 mg/kg/day; 15 mg/kg/day
Administration:

p.o.; daily; 42 days
Result:

Increased systolic blood pressure to 133 mmHg (~17.7% rise vs. saline group) at 15 mg/kg/day dose.
Raised systolic, diastolic, and mean blood pressure in a dose-dependent, statistically significant manner (P < 0.01 vs. saline group).
Increased heart rate in a statistically significant manner only at 15 mg/kg/day dose (P < 0.01 vs. saline group).
Thickened interventricular septum, ventricular wall, and aortic wall, and induced cardiomyocyte hypertrophy in a dose-dependent, statistically significant manner (P < 0.01 vs. saline group).
Induced glomerular vacuoles, hyaline degeneration, reduced glomerular size, and thickened glomerular basement membranes.
Increased aortic ACE and AT1R expression in a dose-dependent, statistically significant manner (P < 0.01 vs. saline group).
Decreased aortic eNOS expression in a dose-dependent, statistically significant manner (P < 0.01 vs. saline group at 15 mg/kg/day dose).
Sharply decreased serum NO concentration (P < 0.01 vs. saline group).

Animal Model:

C57/BL6 (male, 5-6 weeks old, ~20 g, specific pathogen free, hypertension induced by 1 mg/kg/day dexamethasone s.c. daily for 42 days)^[1]
Dosage:

0.15 mg/kg/day; 1.5 mg/kg/day; 15 mg/kg/day
Administration:

p.o.; daily; 42 days; co-administered with 1 mg/kg/day dexamethasone s.c.; daily; 42 days
Result:

Aggravated dexamethasone-induced increases in systolic, diastolic, and mean blood pressure in a dose-dependent, significant manner (P < 0.01 vs. dexamethasone-only group for higher doses).
Increased heart rate significantly at 15 mg/kg/day dose vs. dexamethasone-only group.
Exacerbated dexamethasone-induced aortic wall thickening significantly (P < 0.01 vs. dexamethasone-only group) and glomerular damage.
Increased aortic ACE and AT1R expression significantly compared to dexamethasone-only group.
Decreased aortic eNOS expression in a dose-dependent, significant manner (P < 0.01 vs. dexamethasone-only group).
Slightly further reduced serum NO concentration (not statistically significant vs. dexamethasone-only group).
Saw alleviation of increases in blood pressure, heart rate, and tissue damage, and normalization of ACE, AT1R, and eNOS expression with ACE inhibitor treatment.

Chemical Information

CAS. Nr. 28553-12-0
Appearance Liquid (Density: 0.972 g/cm³)
Molecular Weight 418.61
Formel C₂₆H₄₂O₄
Color Colorless to light yellow
SMILES

O=C(OCCCCCCC(C)C)C1=CC=CC=C1C(OCCCCCCC(C)C)=O
Synonyms

DINP
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (238.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3889 mL

11.9443 mL

23.8886 mL

5 mM

0.4778 mL

2.3889 mL

4.7777 mL

10 mM

0.2389 mL

1.1944 mL

2.3889 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (11.94 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Deng T, et al. Exposure to diisononyl phthalate induced an increase in blood pressure through activation of the ACE/ AT1R axis and inhibition of NO production. Toxicol Lett. 2019;309:42-50. [Content Brief]

[2]. Lington A W, et al. Chronic toxicity and carcinogenic evaluation of diisononyl phthalate in rats[J]. Fundamental and applied toxicology, 1997, 36(1): 79-89.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3889 mL	11.9443 mL	23.8886 mL	59.7215 mL
	5 mM	0.4778 mL	2.3889 mL	4.7777 mL	11.9443 mL
	10 mM	0.2389 mL	1.1944 mL	2.3889 mL	5.9721 mL
	15 mM	0.1593 mL	0.7963 mL	1.5926 mL	3.9814 mL
	20 mM	0.1194 mL	0.5972 mL	1.1944 mL	2.9861 mL
	25 mM	0.0956 mL	0.4778 mL	0.9555 mL	2.3889 mL
	30 mM	0.0796 mL	0.3981 mL	0.7963 mL	1.9907 mL
	40 mM	0.0597 mL	0.2986 mL	0.5972 mL	1.4930 mL
	50 mM	0.0478 mL	0.2389 mL	0.4778 mL	1.1944 mL
	60 mM	0.0398 mL	0.1991 mL	0.3981 mL	0.9954 mL
	80 mM	0.0299 mL	0.1493 mL	0.2986 mL	0.7465 mL
	100 mM	0.0239 mL	0.1194 mL	0.2389 mL	0.5972 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Diisononyl phthalate

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen